// App-Quantinova.ai

4369 : Rearrangements of the erythropoietin receptor are recurrent in Ph-like acute lymphoblastic leukemia and are sensitive to Jak2 inhibition

Researchers

Presenter

  • Ilaria Iacobucci

Principal Investigators

  • Kathryn G. Roberts

  • Yongjin Li

  • Steven M. Kornblau

  • Marina Konopleva

  • Elisabeth Paietta

  • Jacob M. Rowe

  • Ching-Hon Pui

  • Jinghui Zhang

  • Richard C. Harvey

  • Debbie Payne-Turner

  • Marcus Valentine

  • Kelly McCastlain

  • John Easton

  • I-Ming Chen

  • Michael Rusch

Medical Centers

  • Department of Pediatrics and the Helen Diller Family Cancer Center, University of California, San Francisco, CA

  • Center for Childhood Cancer Research, Childrens Hospital of Philadelphia, Philadelphia, PA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM

  • Department of Chemical Biology and Therapeutics, St. Jude Childrens Research Hospital, Memphis, TN

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Janus kinase

Drug/Treatment

  • Erythropoietin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved